April 4, 2019
Gilead Sciences’ HIV triplet Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide fumarate (TAF)) will be launched in Japan on April 8, the company’s Japan arm said on April 3 upon the drug’s addition to the NHI reimbursement price list. Biktarvy...read more